Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000723599 | SCV000114390 | uncertain significance | not provided | 2013-03-12 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000723599 | SCV000237156 | likely benign | not provided | 2021-06-18 | criteria provided, single submitter | clinical testing | Missense variant in a gene in which most reported pathogenic variants are truncating/loss-of-function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002390244 | SCV002697973 | uncertain significance | Cardiovascular phenotype | 2019-10-07 | criteria provided, single submitter | clinical testing | The p.V4909I variant (also known as c.14725G>A), located in coding exon 55 of the TTN gene, results from a G to A substitution at nucleotide position 14725. The valine at codon 4909 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |